CARIS LIFE SCIENCES INC (CAI) Fundamental Analysis & Valuation
NASDAQ:CAI • US1421521071
Current stock price
18.05 USD
-1.15 (-5.99%)
At close:
18.3 USD
+0.25 (+1.39%)
After Hours:
This CAI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. CAI Profitability Analysis
1.1 Basic Checks
- CAI had positive earnings in the past year.
- CAI had a positive operating cash flow in the past year.
- In multiple years CAI reported negative net income over the last 5 years.
- The reported operating cash flow has been mixed in the past 5 years: CAI reported negative operating cash flow in multiple years.
1.2 Ratios
- The Return On Assets of CAI (-47.79%) is comparable to the rest of the industry.
- CAI has a Return On Equity of -93.18%. This is comparable to the rest of the industry: CAI outperforms 45.84% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 3.57%, CAI belongs to the top of the industry, outperforming 88.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47.79% | ||
| ROE | -93.18% | ||
| ROIC | 3.57% |
ROA(3y)-89.95%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Operating Margin, with a value of 5.56%, CAI belongs to the top of the industry, outperforming 89.36% of the companies in the same industry.
- CAI's Operating Margin has declined in the last couple of years.
- CAI's Gross Margin of 66.40% is fine compared to the rest of the industry. CAI outperforms 78.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.56% | ||
| PM (TTM) | N/A | ||
| GM | 66.4% |
OM growth 3YN/A
OM growth 5Y-34.84%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. CAI Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CAI is destroying value.
- Compared to 1 year ago, CAI has more shares outstanding
- Compared to 5 years ago, CAI has more shares outstanding
- Compared to 1 year ago, CAI has an improved debt to assets ratio.
2.2 Solvency
- CAI has an Altman-Z score of 4.19. This indicates that CAI is financially healthy and has little risk of bankruptcy at the moment.
- CAI has a better Altman-Z score (4.19) than 71.95% of its industry peers.
- CAI has a debt to FCF ratio of 5.67. This is a neutral value as CAI would need 5.67 years to pay back of all of its debts.
- Looking at the Debt to FCF ratio, with a value of 5.67, CAI belongs to the top of the industry, outperforming 91.10% of the companies in the same industry.
- A Debt/Equity ratio of 0.66 indicates that CAI is somewhat dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.66, CAI is doing worse than 73.11% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 5.67 | ||
| Altman-Z | 4.19 |
ROIC/WACC0.38
WACC9.45%
2.3 Liquidity
- CAI has a Current Ratio of 7.85. This indicates that CAI is financially healthy and has no problem in meeting its short term obligations.
- CAI's Current ratio of 7.85 is fine compared to the rest of the industry. CAI outperforms 70.60% of its industry peers.
- A Quick Ratio of 7.35 indicates that CAI has no problem at all paying its short term obligations.
- CAI's Quick ratio of 7.35 is fine compared to the rest of the industry. CAI outperforms 68.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.85 | ||
| Quick Ratio | 7.35 |
3. CAI Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 191.16% over the past year.
- Measured over the past years, CAI shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.17% on average per year.
- CAI shows a decrease in Revenue. In the last year, the revenue decreased by -1.64%.
- Measured over the past years, CAI shows a small growth in Revenue. The Revenue has been growing by 4.83% on average per year.
EPS 1Y (TTM)191.16%
EPS 3Y14.52%
EPS 5Y12.17%
EPS Q2Q%121.24%
Revenue 1Y (TTM)-1.64%
Revenue growth 3Y-2.37%
Revenue growth 5Y4.83%
Sales Q2Q%-28.96%
3.2 Future
- Based on estimates for the next years, CAI will show a very negative growth in Earnings Per Share. The EPS will decrease by -19.81% on average per year.
- CAI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.18% yearly.
EPS Next Y83.59%
EPS Next 2Y44.25%
EPS Next 3Y19.27%
EPS Next 5Y-19.81%
Revenue Next Year5.75%
Revenue Next 2Y8.24%
Revenue Next 3Y5.04%
Revenue Next 5Y17.18%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. CAI Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 4.22, which indicates a rather cheap valuation of CAI.
- Based on the Price/Earnings ratio, CAI is valued cheaper than 98.84% of the companies in the same industry.
- CAI is valuated cheaply when we compare the Price/Earnings ratio to 26.78, which is the current average of the S&P500 Index.
- Based on the Price/Forward Earnings ratio of 2.03, the valuation of CAI can be described as very cheap.
- CAI's Price/Forward Earnings ratio is rather cheap when compared to the industry. CAI is cheaper than 99.23% of the companies in the same industry.
- CAI's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.54.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.22 | ||
| Fwd PE | 2.03 |
4.2 Price Multiples
- 89.75% of the companies in the same industry are more expensive than CAI, based on the Enterprise Value to EBITDA ratio.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of CAI indicates a rather cheap valuation: CAI is cheaper than 91.88% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 76.25 | ||
| EV/EBITDA | 69.08 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- A more expensive valuation may be justified as CAI's earnings are expected to grow with 19.27% in the coming years.
PEG (NY)0.05
PEG (5Y)0.35
EPS Next 2Y44.25%
EPS Next 3Y19.27%
5. CAI Dividend Analysis
5.1 Amount
- CAI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CAI Fundamentals: All Metrics, Ratios and Statistics
18.05
-1.15 (-5.99%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26 2026-02-26/amc
Earnings (Next)N/A N/A
Inst Owners43.44%
Inst Owner Change0%
Ins Owners48.61%
Ins Owner Change6.67%
Market Cap5.10B
Revenue(TTM)812.03M
Net Income(TTM)-537.96M
Analysts85.71
Price Target32.92 (82.38%)
Short Float %6.26%
Short Ratio2.95
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)458.54%
Min EPS beat(2)138.66%
Max EPS beat(2)778.42%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)23.74%
Min Revenue beat(2)21.32%
Max Revenue beat(2)26.17%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-12.06%
PT rev (3m)-14.32%
EPS NQ rev (1m)-47.16%
EPS NQ rev (3m)5.74%
EPS NY rev (1m)-34.39%
EPS NY rev (3m)-33.1%
Revenue NQ rev (1m)-0.29%
Revenue NQ rev (3m)2.59%
Revenue NY rev (1m)0.79%
Revenue NY rev (3m)2.74%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.22 | ||
| Fwd PE | 2.03 | ||
| P/S | 6.28 | ||
| P/FCF | 76.25 | ||
| P/OCF | 61.34 | ||
| P/B | 8.84 | ||
| P/tB | 9.14 | ||
| EV/EBITDA | 69.08 |
EPS(TTM)4.28
EY23.71%
EPS(NY)8.91
Fwd EY49.34%
FCF(TTM)0.24
FCFY1.31%
OCF(TTM)0.29
OCFY1.63%
SpS2.87
BVpS2.04
TBVpS1.97
PEG (NY)0.05
PEG (5Y)0.35
Graham Number14.03
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47.79% | ||
| ROE | -93.18% | ||
| ROCE | 4.52% | ||
| ROIC | 3.57% | ||
| ROICexc | 17.82% | ||
| ROICexgc | 19.73% | ||
| OM | 5.56% | ||
| PM (TTM) | N/A | ||
| GM | 66.4% | ||
| FCFM | 8.24% |
ROA(3y)-89.95%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y32.08%
ROICexc growth 3YN/A
ROICexc growth 5Y29.42%
OM growth 3YN/A
OM growth 5Y-34.84%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.72
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 5.67 | ||
| Debt/EBITDA | 5.59 | ||
| Cap/Depr | 71.9% | ||
| Cap/Sales | 2% | ||
| Interest Coverage | 1.04 | ||
| Cash Conversion | 122.78% | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.85 | ||
| Quick Ratio | 7.35 | ||
| Altman-Z | 4.19 |
F-Score6
WACC9.45%
ROIC/WACC0.38
Cap/Depr(3y)44.9%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.78%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)191.16%
EPS 3Y14.52%
EPS 5Y12.17%
EPS Q2Q%121.24%
EPS Next Y83.59%
EPS Next 2Y44.25%
EPS Next 3Y19.27%
EPS Next 5Y-19.81%
Revenue 1Y (TTM)-1.64%
Revenue growth 3Y-2.37%
Revenue growth 5Y4.83%
Sales Q2Q%-28.96%
Revenue Next Year5.75%
Revenue Next 2Y8.24%
Revenue Next 3Y5.04%
Revenue Next 5Y17.18%
EBIT growth 1Y117.55%
EBIT growth 3YN/A
EBIT growth 5Y-20.16%
EBIT Next Year16799.1%
EBIT Next 3Y606.33%
EBIT Next 5Y254.13%
FCF growth 1Y126.37%
FCF growth 3YN/A
FCF growth 5Y3.07%
OCF growth 1Y133.91%
OCF growth 3YN/A
OCF growth 5Y-21.39%
CARIS LIFE SCIENCES INC / CAI Fundamental Analysis FAQ
What is the fundamental rating for CAI stock?
ChartMill assigns a fundamental rating of 5 / 10 to CAI.
Can you provide the valuation status for CARIS LIFE SCIENCES INC?
ChartMill assigns a valuation rating of 9 / 10 to CARIS LIFE SCIENCES INC (CAI). This can be considered as Undervalued.
What is the profitability of CAI stock?
CARIS LIFE SCIENCES INC (CAI) has a profitability rating of 4 / 10.
What is the valuation of CARIS LIFE SCIENCES INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CARIS LIFE SCIENCES INC (CAI) is 4.22 and the Price/Book (PB) ratio is 8.84.
Is the dividend of CARIS LIFE SCIENCES INC sustainable?
The dividend rating of CARIS LIFE SCIENCES INC (CAI) is 0 / 10 and the dividend payout ratio is 0%.